[go: up one dir, main page]

MX2022011729A - Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos. - Google Patents

Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos.

Info

Publication number
MX2022011729A
MX2022011729A MX2022011729A MX2022011729A MX2022011729A MX 2022011729 A MX2022011729 A MX 2022011729A MX 2022011729 A MX2022011729 A MX 2022011729A MX 2022011729 A MX2022011729 A MX 2022011729A MX 2022011729 A MX2022011729 A MX 2022011729A
Authority
MX
Mexico
Prior art keywords
receptor agonist
agonist peptide
peptide compounds
gif
gip receptor
Prior art date
Application number
MX2022011729A
Other languages
English (en)
Inventor
Antoine Charles Olivier Henninot
Derek Cecil Cole
Nicholas Scorah
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2022011729A publication Critical patent/MX2022011729A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación proporciona compuestos peptídicos agonistas del receptor de GIP adecuados para dosificación una vez a la semana (QW), en los que dichos compuestos peptídicos tienen una acción activadora sobre los receptores de GIP, y el uso del péptido agonista del receptor de GIP como medicamento para el tratamiento y/o la prevención de la emesis o un síntoma o una afección asociados con la emesis. Específicamente, se proporciona un péptido agonista del receptor de GIP que contiene una secuencia representada por cualquiera de las fórmulas (I)-(V) o una sal de este y un medicamento que lo comprende.
MX2022011729A 2020-03-25 2021-03-25 Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos. MX2022011729A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062994721P 2020-03-25 2020-03-25
PCT/JP2021/014422 WO2021193983A2 (en) 2020-03-25 2021-03-25 Qw dosing of gip receptor agonist peptide compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2022011729A true MX2022011729A (es) 2022-10-13

Family

ID=75674909

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011729A MX2022011729A (es) 2020-03-25 2021-03-25 Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos.

Country Status (18)

Country Link
US (1) US20230143604A1 (es)
EP (1) EP4126920A2 (es)
JP (1) JP2023524603A (es)
KR (1) KR20220157409A (es)
CN (1) CN115916812A (es)
AR (1) AR121649A1 (es)
AU (1) AU2021243671A1 (es)
BR (1) BR112022019110A2 (es)
CA (1) CA3172241A1 (es)
CL (1) CL2022002597A1 (es)
CO (1) CO2022014960A2 (es)
EC (1) ECSP22074715A (es)
IL (1) IL296219A (es)
MX (1) MX2022011729A (es)
PE (1) PE20221727A1 (es)
PH (1) PH12022552561A1 (es)
TW (1) TW202202517A (es)
WO (1) WO2021193983A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023288313A1 (en) * 2021-07-16 2023-01-19 Pep2Tango Therapeutics Inc. Compositions including multi-agonist peptides and methods of manufacture and use
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
WO2025154020A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154021A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
PE20040609A1 (es) 2002-11-01 2004-10-29 Takeda Pharmaceutical Compuestos heterociclicos aromaticos como promotores de un factor neurotrofico
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
CA2507026A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
WO2004106276A1 (ja) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited 縮合環化合物
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
TW200523247A (en) 2003-12-25 2005-07-16 Takeda Pharmaceutical 3-(4-benzyloxyphenyl) propanoic acid derivatives
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
EP1731505B1 (en) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
JP5094394B2 (ja) 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
WO2006121904A1 (en) * 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical COMPOUND OF PHENOXYALKANOIC ACID
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
MX2008001386A (es) 2005-08-10 2008-04-07 Takeda Pharmaceutical Agente terapeutico para diabetes.
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
ES2450081T3 (es) 2006-06-27 2014-03-21 Takeda Pharmaceutical Company Limited Compuestos cíclicos condensados como moduladores del receptor GPR40
CA2660835A1 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable propperties
WO2008047821A1 (en) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN101573357B (zh) 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
JP2011502958A (ja) 2007-06-19 2011-01-27 武田薬品工業株式会社 グルコキナーゼ活性化インダゾール化合物
JP2011530509A (ja) * 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Ｎ末端において修飾されたグルコース依存性インスリン分泌刺激ポリペプチド（ｇｉｐ）のアナログ
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
JOP20180028A1 (ar) * 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
AR121650A1 (es) * 2020-03-25 2022-06-22 Takeda Pharmaceuticals Co Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos

Also Published As

Publication number Publication date
AR121649A1 (es) 2022-06-22
BR112022019110A2 (pt) 2023-01-17
PE20221727A1 (es) 2022-11-04
PH12022552561A1 (en) 2024-04-22
WO2021193983A3 (en) 2021-11-04
WO2021193983A2 (en) 2021-09-30
EP4126920A2 (en) 2023-02-08
WO2021193983A8 (en) 2023-05-25
CL2022002597A1 (es) 2023-06-02
US20230143604A1 (en) 2023-05-11
IL296219A (en) 2022-11-01
KR20220157409A (ko) 2022-11-29
CO2022014960A2 (es) 2022-11-08
ECSP22074715A (es) 2022-10-31
CN115916812A (zh) 2023-04-04
JP2023524603A (ja) 2023-06-12
CA3172241A1 (en) 2021-09-30
TW202202517A (zh) 2022-01-16
AU2021243671A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
MX2022011729A (es) Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos.
ECSP22074680A (es) Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos
CO2019012271A2 (es) Péptido activador de receptor de gip
CL2019000663A1 (es) Derivado de pirazolopiridina que tiene el efecto agonista del receptor de glp-1.
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
ECSP15044389A (es) Compuesto peptídico
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
MX2023011675A (es) Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia.
MX2019014104A (es) Compuesto novedoso de bifenilo o sal del mismo.
MX2018006503A (es) Compuesto novedoso de bifenilo o una sal del mismo.
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
MX2021014049A (es) Compuestos espiro triciclicos.
DOP2017000156A (es) Derivados de glucagón con estabilidad mejorada
CL2017001024A1 (es) Formulación de buprenorfina inyectable
MX2021015654A (es) Antagonista del receptor 2 de prostaglandina e2 (ep2).
AR108806A1 (es) Solución de dexmedetomidina lista para el uso, premezclada, esterilizable por calor, envasada en un recipiente de plástico flexible
ECSP18084449A (es) Dispositivo de inyección mecánico para descargar múltiples formulaciones líquidas, incluso vacunas
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
CO2022015630A2 (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
MX2018008671A (es) Composicion para incrementar la expresion de pgc-1alfa.
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
CO2020002967A2 (es) Desinfectante novedoso para criaderos
AR102248A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes
UY37412A (es) Compuestos de indazol para uso en lesiones de tendones y/o ligamentos
AR107750A1 (es) Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos